Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
T cell responses shape infant SIV reservoirs and postintervention control after AAV9-eCD4-Ig and latency reversal
Jairo A. Fonseca, Alexis C. King, Kaleaha S. Davis, Daniel O’Hagan, Adrian Khoei, Lucas Alves Britto Da Costa, Camryn Cockerham, Mackenzie Cottrell, Stephanie Ehnert, Jennifer S. Wood, Michael D. Alpert, Matthew R. Gardner, Jeffrey D. Lifson, Maud Mavigner, Mauricio A. Martins, Ann Chahroudi
Jairo A. Fonseca, Alexis C. King, Kaleaha S. Davis, Daniel O’Hagan, Adrian Khoei, Lucas Alves Britto Da Costa, Camryn Cockerham, Mackenzie Cottrell, Stephanie Ehnert, Jennifer S. Wood, Michael D. Alpert, Matthew R. Gardner, Jeffrey D. Lifson, Maud Mavigner, Mauricio A. Martins, Ann Chahroudi
View: Text | PDF
Research Article AIDS/HIV Immunology Infectious disease

T cell responses shape infant SIV reservoirs and postintervention control after AAV9-eCD4-Ig and latency reversal

  • Text
  • PDF
Abstract

Early antiretroviral therapy (ART) limits viral reservoir establishment in infants but also constrains virus-specific immunity required to clear reactivated cells. In the early ART context, we evaluated whether combining adeno-associated virus serotype 9–vectored (AAV9-vectored) eCD4-IgG1 with pharmacological latency reversal using the second mitochondria-derived activator of caspases (SMAC) mimetic AZD5582 could promote reservoir reduction and control in SIV-infected infant macaques. AAV9 delivery achieved sustained eCD4-IgG1 expression, and AZD5582 induced on-ART viremia, but the combination did not reduce intact SIV proviral DNA relative to controls. Partial postintervention control of viremia during analytical treatment interruption (ATI) occurred in 2 of 6 infants receiving AAV9-eCD4-IgG1 plus AZD5582 with restricted reservoir expansion during recrudescence at week 13. Intact reservoir size during ATI correlated inversely with on-ART viremia during AZD5582 treatment. Animals were classified as controllers or non-controllers. Controllers did not show increased eCD4-IgG1 expression nor increased on-ART viremia during AZD5582 treatment but harbored less pre-ART intact SIV DNA in PBMCs than non-controllers. Controllers also exhibited higher frequencies and greater polyfunctionality of virus-specific CD8+ T cells prior to ATI. These findings suggest immune control of reservoir size and post-ART viral dynamics in early-treated infants and that AAV9-eCD4-IgG1 plus AZD5582 increases the likelihood of post-ART viral control.

Authors

Jairo A. Fonseca, Alexis C. King, Kaleaha S. Davis, Daniel O’Hagan, Adrian Khoei, Lucas Alves Britto Da Costa, Camryn Cockerham, Mackenzie Cottrell, Stephanie Ehnert, Jennifer S. Wood, Michael D. Alpert, Matthew R. Gardner, Jeffrey D. Lifson, Maud Mavigner, Mauricio A. Martins, Ann Chahroudi

×

Figure 5

Virological predictors of posttreatment control after analytical treatment interruption.

Options: View larger image (or click on image) Download as PowerPoint
Virological predictors of posttreatment control after analytical treatme...
(A–D) Comparison of controllers (n = 2) and non-controllers (n = 10) for geometric mean plasma viral load during early infection (A; weeks 1–3 after infection) and suppressive ART (B; weeks 4–36 after infection), and for intact SIV proviral DNA at ART initiation in PBMCs (C) and lymph node mononuclear cells (LNMCs) (D). Data are presented descriptively. (E–G) Linear regression of geometric mean plasma viral load during suppressive ART against intact SIV proviral DNA in PBMCs at week 13 after ATI, across all ATI cohort animals (E; n = 12) and separately in intervention (F; n = 6) and control (G; n = 6) animals. Solid lines indicate linear regression fits, and dashed lines indicate 95% CI bounds. (H and I) Partial Pearson’s correlations between geometric mean plasma viremia during the AZD5582 dosing phase in intervention animals or matched time points in control animals and intact SIV proviral DNA in PBMCs at week 13 after ATI, adjusted for geometric mean plasma viral load during suppressive ART, in intervention (H; n = 6) and control (I; n = 6) animals. Pearson’s correlation coefficients (r), coefficients of determination (R2), and exact P values are shown in E–G; partial correlation coefficients (r) and exact P values are shown in H and I. Each symbol represents an individual animal identified in the figure key. In A–E, controllers are shown in red, intervention non-controllers as filled black symbols, and control non-controllers as open black symbols. In F–I, controllers are shown in red, intervention non-controllers as filled blue symbols, and control non-controllers as open orange symbols.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts